此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Return to Activity After Surgery for Lumbar Disc Herniation

2026年6月18日 更新者:Intrinsic Therapeutics

Return to Activity After Surgery for Lumbar Disc Herniation: An Exploratory, Post-Market, Prospective, Randomized, Controlled Trial of an Annular Closure Device

RCT investigating postoperative activity restriction after lumbar discectomy in patients treated with annular closure.

研究概览

详细说明

The purpose of this prospective, randomized, multicenter study is to determine the reherniation and reoperation rates of patients treated with the annular closure device after standard post-operative restrictions versus patient-determined restrictions.

研究类型

介入性

注册 (估计的)

120

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Kelsey Miller-Torchia A SVP, Clinical & Business Development, BA
  • 电话号码:322 7819320222
  • 邮箱:kmiller@barricaid.com

研究联系人备份

  • 姓名:Ivan Grzan Sr. Dir. Professional Education, BA
  • 电话号码:7819320222
  • 邮箱:ivan@in-thera.com

学习地点

    • Louisiana
      • Shreveport、Louisiana、美国、71101
        • Spine Institute of Louisiana
        • 首席研究员:
          • Pierce Nunley, MD
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Skeletally mature (male or female).
  • Patients with posterior or posterolateral disc herniations at one level between L4 and S1 with radiographic confirmation of neural compression using MRI. [Note: Intraoperatively, only patients with an annular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.]
  • Minimum posterior disc height of 5mm at the index level.
  • Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees)22 (L45, L5S1)
  • VAS leg pain (one or both legs) of at least 40/100 at baseline
  • Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.
  • Implanted with annular closure device.

Exclusion Criteria:

  • Spondylolisthesis Grade II or higher (25% slip or greater).
  • Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed).
  • Subject has been diagnosed with active hepatitis, AIDS, or HIV.
  • Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease.
  • Subject has a known allergy to titanium, polyethylene or polyester materials.
  • Any subject that cannot have a baseline MRI taken.
  • Subject is pregnant or interested in becoming pregnant in the next year.
  • Subject has active tuberculosis or has had tuberculosis in the past three (3) years.
  • Subject has a history of active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years.
  • Subject is immunologically suppressed, received steroids >1 month over the past year.
  • Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery.
  • Subject has a current chemical/alcohol dependency or significant psychosocial disturbance.
  • Subject has a life expectancy of less than three (3) years.
  • Subject is currently involved in active spinal litigation (Workers' compensation patients may be included.
  • Subject is currently involved in another investigational study.
  • Subject is incarcerated.
  • Subject has back or non-radicular leg pain of unknown etiology.
  • Prior surgery at the index lumbar vertebral level.
  • Subject requiring a spine DEXA (i.e., patients with SCORE of ≥ 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used.
  • Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology.
  • Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip.
  • Subject has scoliosis of greater than ten (10) degrees (both angular and rotational).
  • Any metabolic bone disease.
  • Subject has an active infection either systemic or local.
  • Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction.
  • Subject has severe arterial insufficiency of the legs or other peripheral vascular disease. (Screening on physical examination for patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded.)
  • Subject has significant peripheral neuropathy, patient defined as a patient with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities.
  • Subject has insulin-dependent diabetes mellitus.
  • Subject is morbidly obese (defined as a body mass index >40 or weighs more than 100 lbs. over ideal body weight).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Non restricted postoperative instructions
Investigating different postoperative restrictions after lumbar disc herniation surgery
有源比较器:Restricted postoperative instructions
Investigating different postoperative restrictions after lumbar disc herniation surgery

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Symptomatic reherniation
大体时间:3 Months
No symptomatic reherniation at the index level (on either side)
3 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:David H Kim, MD、Atrius Health

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年6月30日

初级完成 (估计的)

2027年10月1日

研究完成 (估计的)

2027年10月31日

研究注册日期

首次提交

2026年6月18日

首先提交符合 QC 标准的

2026年6月18日

首次发布 (实际的)

2026年6月25日

研究记录更新

最后更新发布 (实际的)

2026年6月25日

上次提交的符合 QC 标准的更新

2026年6月18日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

No external collaboration expected

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅